Favipiravir

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Synonym(s)

Avigan; T-705

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Antiviral, RNA polymerase inhibitor. Favipiravir is mainly used in the therapy of influenza, but is also effective against a number of other RNA viruses. Favipiravir belongs to the pyrazine carboxamides (molecular formula C5H4FN3O2; structural formula see figure).

Pharmacodynamics (Effect)This section has been translated automatically.

Favipiravir is a selective inhibitor of the RNA polymerase in RNA viruses. the viral RNA-dependent RNA- avipiravir polymerase of various viruses, but not of cellular polymerases. Favipiravir is effective against:

the influenza virus

West Nile Virus

the yellow fever virus

the foot-and-mouth disease virus

various flaviviruses, arena viruses, bunyaviruses, alpha viruses

various enteroviruses

the Ebola virus

the Rift Valley Virus.

Many viruses, including the Ebola virus, need the enzyme to transcribe their genes into m-RNA, which is accepted by the ribosomes, the protein factories of the cells. Favipiravir prevents this and thus interrupts viral replication.

Note(s)This section has been translated automatically.

Favipiravir was used during the Ebola fever epidemic in 2014 as an emergency measure without the usually necessary drug approval for humans. On February 16, 2020, favipiravir received short-term approval for five years as an effective antiviral against COVID-19.

LiteratureThis section has been translated automatically.

  1. Caroline AL et al (2014) Broad Spectrum Antiviral Activity of Favipiravir (T-705): Protection from Highly Lethal Inhalational Rift Valley Fever. PLoS Neglected Tropical Diseases 8: e2790.

Authors

Last updated on: 29.10.2020